Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1/2 1

Status

Unknown 9Completed 8Recruiting 5Terminated 2Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 123INDUSTRY 67OTHER_GOV 5NIH 5NETWORK 4

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Stomach Neoplasms 3Pancreatic Neoplasms 1Colorectal Neoplasms 1

Interventions

Drug Therapy 10pembrolizumab 9Bevacizumab 9Radiotherapy 8Cyclophosphamide 8Carboplatin 8Oxaliplatin 7tislelizumab 6Surgical Procedures, Operative 6Docetaxel 6Cisplatin 6Capecitabine 6Paclitaxel 5Nivolumab 5Fluorouracil 5Control Groups 5fludarabine 4Immune Checkpoint Inhibitors 4Gemcitabine 4Endoscopic Mucosal Resection 4sintilimab 3Trastuzumab 3Pemetrexed 3Neoadjuvant Therapy 3Leucovorin 3Laparoscopy 3Irinotecan 3Injections 3Hematologic Tests 3HMPL-013 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × OTHER_GOV × Fluorouracil × Clear all
NCT07542002 2026-04-21

Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pancreatic Cancer With Risk Factors:A Prospective Exploratory Study

Ningbo Medical Center Lihuili Hospital

Phase 2 Recruiting
37 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT06313801 2025-11-21

Comparing the Safety and Efficacy of First-line Polychemotherapy and Polychemotherapy in Combination With PIPAC Sessions

Nizhny Novgorod Regional Clinical Oncology Center

Phase 2 Recruiting
106 enrolled
Gastrointestinal

Stomach Neoplasms

NCT04776655 2025-10-02

LIBImAb

Azienda USL Reggio Emilia - IRCCS

Phase 3 Recruiting
280 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT06793917 2025-07-20

Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

Fujian Cancer Hospital

Phase 3 Recruiting
269 enrolled
Gastrointestinal

Stomach Neoplasms

NCT05319639 2025-02-27

Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab

Fujian Cancer Hospital

Phase 1/2 Recruiting
51 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡